Growth factor treatment prior to low-dose total body irradiation increases donor cell engraftment after bone marrow transplantation in mice

Blood

Volumn 100, Issue 1, 2002, Pages 312-317

  Noach, Estelle J K ^a   Ausema, Albertina ^a   Dillingh, Jan H ^a   Dontje, Bert ^a   Weersing, Ellen ^a   Akkerman, Imre ^a   Vellenga, Edo ^a   De Haan, Gerald ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 11; STEM CELL FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL COUNT; CHIMERA; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; WHOLE BODY RADIATION;

EID: 0036660178     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.312     Document Type: Article

References (45)

1. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755-1759.
2. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
3. Slavin S, Nagler A, Varadi G, Or R. Graft vs auto-immunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol. 2000;28:853-857.
4. Slavin S, Nagler A. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. Ann Oncol. 1998; 9(suppl)1:31-39.
5. Singhal S, Safdar A, Chiang KY, etal. Non-myeloablative allogeneic transplantation ("microallograft") for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. Bone Marrow Transplant. 2000;26:1231-1233.
6. Gomez-Almaguer D, Ruiz-Arguelles GJ, Ruiz-Arguelles A, Gonzalez-Llano O, Cantu OE, Hernandez NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant. 2000;25:131-133.
7. Rosenzweig M, MacVittie TJ, Harper D, et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood. 1999;94:2271-2286.
8. Maze R, Hanenberg H, Williams DA. Establishing chemoresistance in hematopoietic progenitor cells. Mol Med Today. 1997;3:350-358.
9. James RI, Warlick CA, Diers MD, Gunther R, McIvor RS. Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity. Blood. 2000;96:1334-1341.
10. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol. 1997;99:9-22.
11. Moore MAS. Stem cell proliferation: Ex vivo and in vivo observations. Stem Cells. 1997;15:239-248.
12. Hardy CL. The homing of hematopoietic stem cells to the bone marrow. Am J Med Sci. 1995; 309:260-266.
13. Szilvassy SJ, Bass MJ, Van Zant G, Grimes B. Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by ex vivo expansion. Blood. 1999;93:1557-1566.
14. Cui JS, Wahl RL, Shen TL, et al. Bone marrow cell trafficking following intravenous administration. Br J Haematol. 1999;107:895-902.
15. Stewart FM, Crittenden RB, Lowry PA, Pearson WS, Quesenberry PJ. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood. 1993;81:2566-2571.
16. Tomita Y, Sachs DH, Sykes M. Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow. Blood. 1994;83;939-948.
17. Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1319-1339.
18. Stewart FM, Zhong S, Wuu J, Hsieh C, Nilsson SK, Quesenberry PJ. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood. 1998;91:3681-3687.
19. Quesenberry PJ, Ramshaw H, Crittenden RB, et al. Engraftment of normal murine marrow into nonmyeloablated host mice. Blood Cells. 1994;20:348-350.
20. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000;106:1331-1339.
21. Yamaguchi M, Ikebuchi K, Hirayama F, et al. Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in G(0)/G(1) versus S+G(2)/M phases of the cell cycle. Blood. 1998;92:842-848.
22. Habibian HK, Peters SO, Hsieh CC, et al. The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. J Exp Med. 1998;188:393-398.
23. Wiesmann A, Kim M, Georgelas A, et al. Modulation of hematopoietic stem/progenitor cell engraftment by transforming growth factor beta. Exp Hematol. 2000;28:128-139.
24. Monette F, DeMello J. The relationship between stem cell seeding efficiency and position in cell cycle. Cell Tissue Kinet. 1979;12:161-175.
25. van Os R, Dawes D, Mislow JMK, Witsell A, Mauch PM. Host conditioning with 5-fluorouracil and kit-ligand to provide for long-term bone marrow engraftment. Blood. 1997;89:2376-2383.
26. Molineux G, Migdalska A, Haley J, Evans GS, Dexter TM. Total marrow failure induced by pegylated stem-cell factor administered before 5-fluorouracil. Blood. 1994;83:3491-3499.
27. Fleming WH, Alpern EJ, Uchida N, Ikuta K, Weissman IL. Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo. Proc Natl Acad Sci U S A. 1993;90:3760-3764.
28. de Haan G, Loeffler M, Nijhof, W. Long-term recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment severely depresses murine marrow erythropoiesis without causing an anemia. Exp Hematol. 1992;20:600-604.
29. de Haan G, Dontje B, Engel Ch, Loeffler M, Nijhof W. Prophylactic pretreatment of mice with hematopoietic growth factors induces expansion of primitive cell compartments and results in protection against 5-fluorouracil-induced toxicity. Blood. 1996;87:4581-4588.
30. Chervenick PA, Boggs DR, Marsh JC, Cartwright GE, Wintrobe MM. Quantitative studies of blood and bone marrow neutrophils in normal mice. Am J Physiol. 1968;215:353-360.
31. Briganti G, Covelli V, Silini G, Srivastava PN. The distribution of erythropoietic bone marrow in the mouse. Acta Haematol. 1970;44:355-361.
32. Ploemacher RE, van der Sluijs JP, Voerman JSA, Brons NHC. An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood. 1989;74:2755-2763.
33. Ploemacher RE, van der Sluijs JP, van Beurden AJ, Baert MRM, Lam Chan P. Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse. Blood. 1991;78:2527-2533.
34. Down JD, de Haan G, Dillingh JH, Dontje B, Nijhof W. Stem cell factor has contrasting effects in combination with 5-fluorouracil or total-body irradiation on frequencies of different hemopoietic cell subsets and engraftment of transplanted bone marrow. Radiat Res. 1997;147:680-685.
35. de Wit R, Verweij J, Bontenbal M, et al. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst. 1996;88:1393-1398.
36. van Os R, Robinson S, Sheridan T, Mislow JM, Dawes D, Mauch PM. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood. 1998;92:1950-1956.
37. Mardiney M, Malech HL. Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood. 1996;87:4049-4056.
38. Nikolic B, Sykes M. Mixed hematopoietic chimerIsm and transplantation tolerance. Immunol Res. 1997;16:217-228.
39. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation. 1999;68:459-467.
40. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234-3241.
41. Simpson E. The role of H-Y as a minor transplantation antigen. Immunol Today. 1982;3:97-106.
42. van Os R. Radiobiologlcal studies on target cell populations in murine bone marrow transplantation recipients. Thesis Rijksuniversiteit Groningen, The Netherlands; 1994:1-186.
43. van Os R, Sheridan TM, Robinson S, Drukteinis D, Ferrara JLM, Mauch PM. Immunogenicity of Ly5 (CD45)-antigens hampers long-term engraftment following minimal conditioning in a murine bone marrow transplantation model. Stem Cells. 2001;19:80-87.
44. Wekerle T, Sayegh MH, Ito H, et al. Anti-CD154 or CTLA41g obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation. 1999;68: 1348-1355.
45. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998;187: 2037-2044.